We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-10%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.64B
AUM Growth
-$98.2M
Cap. Flow
+$187M
Cap. Flow %
11.36%
Top 10 Hldgs %
46.02%
Holding
79
New
7
Increased
13
Reduced
45
Closed
4

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.9M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$23.3M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$18.4M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$18.2M
5
QURE icon
uniQure
QURE
+$17.3M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$20.8M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$15.6M
3
ALLK
Allakos
ALLK
+$13.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.3M
5
ANAB icon
AnaptysBio
ANAB
+$5.18M

Sector Composition

Rank Sector Weight
1 Healthcare 82.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$133M 8.11%
3,541,367
+419,000
+13% +$18.2M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$125M 7.59%
1,600,000
+500,000
+45% +$46.9M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$119M 7.23%
+400,000
New +$118M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$71.7M 4.36%
2,976,000
+9,892
+0.3% +$272K
RETA
5
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$65.8M 4.01%
819,769
+13,619
+2% +$1.16M
BBIO icon
6
BridgeBio Pharma
BBIO
$16.4B
$56.2M 3.42%
2,617,566
-163,319
-6% -$4.52M
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$53.5M 3.25%
1,281,400
-268,600
-17% -$11.3M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.5B
$45.1M 2.75%
468,300
+68,300
+17% +$7.62M
CRSP icon
9
CRISPR Therapeutics
CRSP
$4.69B
$44.4M 2.71%
1,084,300
+384,300
+55% +$18.4M
MRTX
10
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$42.9M 2.61%
+550,000
New +$51.6M
STOK icon
11
Stoke Therapeutics
STOK
$1.84B
$38.4M 2.34%
1,788,394
-81,286
-4% -$2.27M
PRNB
12
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$37.9M 2.31%
1,341,896
-20,002
-1% -$734K
BPMC
13
DELISTED
Blueprint Medicines
BPMC
$36.2M 2.2%
493,000
+143,000
+41% +$12.4M
QURE icon
14
uniQure
QURE
$2.78B
$35.4M 2.16%
900,000
+300,000
+50% +$17.3M
ALLK
15
DELISTED
Allakos
ALLK
$34.9M 2.13%
444,100
-205,900
-32% -$13.6M
TCDA
16
DELISTED
Tricida, Inc. Common Stock
TCDA
$33.4M 2.03%
1,082,880
-95,095
-8% -$3.19M
AXNX
17
DELISTED
Axonics, Inc. Common Stock
AXNX
$32.9M 2%
1,222,671
-29,824
-2% -$1.04M
XBI icon
18
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$30.5M 1.86%
400,000
-500,000
-56% -$41.6M
QTNT
19
DELISTED
Quotient Limited Ordinary Shares
QTNT
$28.3M 1.72%
91,050
-3,950
-4% -$1.52M
NXTC icon
20
NextCure
NXTC
$20.4M
$27.3M 1.66%
73,717
-9,616
-12% -$3.13M
DCPH
21
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$26.8M 1.63%
+788,500
New +$23.3M
BHVN
22
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$25M 1.52%
600,000
+50,000
+9% +$2.11M
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$343M
$24.7M 1.51%
2,123,760
+49,165
+2% +$610K
ASND icon
24
CALL
Ascendis Pharma A/S
ASND
$16.5B
$24.1M 1.47%
250,000
– –
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.1M 1.41%
443,000
-57,000
-11% -$3.03M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Cormorant Asset Management held 79 positions worth $1.64B, down 5.6% from $1.74B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $187M of net new capital in Q3 2019, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Allakos, an estimated $13.6M trimmed.

  • Cormorant Asset Management's largest Q3 2019 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.
  • Cormorant Asset Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $46.9M increase.
  • Cormorant Asset Management's biggest Q3 2019 reduction was Allakos, cutting an estimated $13.6M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $20.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.64B portfolio in Q3 2019.
  • Cormorant Asset Management opened 7 new positions and closed 4 in Q3 2019.
  • Cormorant Asset Management's portfolio value fell 5.6% quarter-over-quarter to $1.64B.

Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.